Zobrazeno 1 - 10
of 336
pro vyhledávání: '"YJ Bignon"'
Autor:
W Troudi, N Uhrhammer, K Ben Romdhane, C Sibille, W Mahfoudh, L Chouchane, F Ben Ayed, YJ Bignon, A Ben Ammar Elgaaied
Publikováno v:
European Journal of Histochemistry, Vol 51, Iss 3, Pp 219-226 (2009)
BRCA1 is a tumor suppressor gene which is inactivated by mutation in familial breast and ovarian cancers. Over 300 different disease causing germ-line mutations have been described; 60% are unique to an individual family. This diversity and the large
Externí odkaz:
https://doaj.org/article/76f701b9a17845c8ae15091902fe8c38
Autor:
Ollier M, Radosevic-Robin N, Kwiatkowski F, Ponelle F, Viala S, Privat M, Uhrhammer N, Bernard-Gallon D, Penault-Llorca F, Yj, Bignon, Yannick Bidet
Publikováno v:
American Journal of Cancer Research
American Journal of Cancer Research, e-Century Publishing, 2015, 5 (7), pp.2113-2126
Europe PubMed Central
Scopus-Elsevier
American Journal of Cancer Research, e-Century Publishing, 2015, 5 (7), pp.2113-2126
Europe PubMed Central
Scopus-Elsevier
International audience; Among breast cancers, 10 to 15% of cases would be due to hereditary risk. In these familial cases, mutations in BRCA1 and BRCA2 are found in only 15% to 20%, meaning that new susceptibility genes remain to be found. Triple-neg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::788b8ef41d9883df5e934acca8534d86
https://hal.archives-ouvertes.fr/hal-01647099
https://hal.archives-ouvertes.fr/hal-01647099
Autor:
Troudi W, Uhrhammer N, Ben Romdhane K, Sibille C, Wijden Mahfoudh, Chouchane L, Ben Ayed F, Yj, Bignon, Ben Ammar Elgaaied A
Publikováno v:
European Journal of Histochemistry, Vol. 51, no. 3, p. 219-226 (2007)
European Journal of Histochemistry, Vol 51, Iss 3, Pp 219-226 (2009)
Europe PubMed Central
European Journal of Histochemistry, Vol 51, Iss 3, Pp 219-226 (2009)
Europe PubMed Central
BRCA1 is a tumor suppressor gene which is inactivated by mutation in familial breast and ovarian cancers. Over 300 different disease causing germ-line mutations have been described; 60% are unique to an individual family. This diversity and the large
Autor:
Francois Eisinger, Thouvenin D, Yj, Bignon, Cuisenier J, Feingold J, Hoerni B, Lasset C, Lyonnet D, Maraninchi D, Marty M
Publikováno v:
Europe PubMed Central
Publikováno v:
Europe PubMed Central
In spite of the use of molecular biology, the cellular lineage and clonality of Reed-Sternberg cells, the abnormal cells of Hodgkin's disease, remain an enigma. We studied the pattern of rearrangements at immunoglobulin and T-cell receptor loci in 23
Autor:
Yj, Bignon, Souteyrand P, Roger H, Fonck Y, Bernard D, Chassagne J, Ramos F, D'Incan M, philippe chollet, Dastugue B
Publikováno v:
Europe PubMed Central
The antigen receptor genes studied (immunoglobulin gene for B-cells, and T-cell receptor -beta or -gamma gene for T-cells) represent the most powerful tools for diagnosing the clonality of a lymphoid lineage. We have clonotyped 23 cutaneous T-cell ly
Publikováno v:
médecine/sciences. 15:1086
L'ataxie-telangiectasie est une maladie genetique hereditaire rare, caracterisee par une degenerescence cerebelleuse, un deficit immunitaire, une augmentation de la sensibilite aux radiations ionisantes et un risque plus eleve de cancer. Depuis le cl
Autor:
Yj, Bignon, Dauplat J, Jp, Ferrière, Legros M, philippe chollet, Jp, Boiteux, Giraud B, Plagne R
Publikováno v:
Europe PubMed Central
Recent results with the therapeutic strategy for malignant testicular tumors are presented. Nearly 80% of these tumors can be cured by the coordinated therapeutic efforts of a surgeon and medical oncologist. Cis-platinum chemotherapy regimens are wid
Autor:
Millour M, Charbonnel C, Florencce Magrangeas, Minvielle S, Campion L, Gouraud W, Campone M, Déporte-Féty R, Yj, Bignon, Penault-Llorca F, Jézéquel P
Publikováno v:
Europe PubMed Central
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::97a2bf66acd57cc8d8a594dc2c578887
http://europepmc.org/abstract/med/31394686
http://europepmc.org/abstract/med/31394686
Publikováno v:
Europe PubMed Central
Adjuvant medical treatments (chemotherapy or endocrine therapy) are now used in the vast majority of women with breast cancer. They delay recurrences and reduce their number, the increase in survival being particularly marked in limited forms. They a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6bf29bbc2499a3e79ca8155cb3363f38
http://europepmc.org/abstract/med/2183339
http://europepmc.org/abstract/med/2183339